Richard E Scranton MD

Physician

1620 Tremont StreetBrigham And Womens Hospital Division Of AgingBoston, MA 02120
Phone+1 617-525-7631

Dr. Scranton is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Scranton's full profile Already have an account?

Education & Training

Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1994 - 1997
East Tennessee State University James H. Quillen College of MedicineClass of 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2000 - 2018

Clinical Trials

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes Start of enrollment: 2004 Jul 01
Completed
Phase 3
Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin Start of enrollment: 2005 Feb 01
Terminated
Phase 3

Publications & Presentations

PubMed

2 citations
Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial.
Leslie Citrome, Nayana Nagaraj, Giovanni Traverso, Todd Dumas, Richard Scranton
The Lancet. Psychiatry. 2025-07-01
A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys.
Richard W Foltin, Stephen Zale, Kristine A Sykes, Nayana Nagaraj, Richard E Scranton
Drug and Alcohol Dependence. 2022-10-01
17 citations
Randomized trial of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery with or without intrathecal morphine
Ashraf S. Habib, Srdjan S. Nedeljkovic, Jean-Louis Horn, Richard M. Smiley, Attila G Kett
Journal of Clinical Anesthesia. 2021-10-06

Press Mentions

Weekly Schizophrenia Pill Produces Promising Results in Final-Stage TrialJune 12th, 2025
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective DisorderMay 9th, 2023
Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDAJuly 27th, 2021